maternal use androgens high doses certain weakly androgenic synthetic progestogens progestins structurally related testosterone masculinize virilize vulva female fetus susceptible times degree fusion labioscrotal folds urogenital folds clitoral enlargement occur exposure occurs week gestation clitoral enlargement occur exposure occurs cases result ambiguous fetal masculinization vulva usually due enzyme abnormalities involved adrenal steroid biosynthesis resulting congenital adrenal hyperplasia cah fetal masculinization vulva much less frequently due maternal use androgenic fetal masculinization vulva due maternal use androgenic steroids generally less advanced due cah unlike cah cause progressive affected females mature normally normal fertility almost total regression genital anomaly cases simple clitoral enlargement even severe cases surgical correction labioscrotal fusion relatively incidence fetal masculinization vulva varies drug sex steroid currently utilized women cause virilization female fetuses administered usually administered doses androgen danazol derivative ethisterone fetal masculinization vulva resulted doses danazol low mgday whereas mgday usual initial dose danazol used treat severe general pregnane derivatives eg progesterone dydrogesterone hydroxyprogesterone caproate medroxyprogesterone acetate megestrol acetate virilize even high dose testosterone derivatives ethisterone norethisterone norethisterone acetate etc generally virilize exceptions eg noretynodrel allylestrenol progestogens currently used pregnancy eg luteal support ivf protocols prevention preterm birth pregnant women history least one spontaneous preterm birth progesterone hydroxyprogesterone caproate dydrogesterone doses required virilization mgday far excess associated inadvertent contraceptive exposure genital ambiguity due progestin exposure pregnancy thus mostly topic historical first drugs reported cause fetal masculinization androgens methandriol methyltestosterone june fda approved androgen danazol danocrine derivative ethisterone treatment endometriosis warning use pregnancy contraindicated risk masculinization vulvas female first case report fetal masculinization vulva female infant born mother inadvertently treated pregnancy danazol published manufacturer danocrine winthrop laboratories received reports worldwide pregnant women exposed danazol completed pregnancies birth female infants virilized pattern clitoromegaly fused labia urogenital sinus formation genital reconstructive surgery usually always required childhood likely true rate occurrence much less many cases normal outcome would reported genital anomalies reported danazol therapy discontinued week warnings use danazol progressively strengthened fda required black box warning use danazol pregnancy contraindicated exposure danazol utero may result androgenic effects female fetus causing vulvar masculinization black box warning recommends sensitive hcgÎ²subunit pregnancy test immediately prior starting danazol therapy use nonhormonal method contraception published reports fetal masculinization vulva studies suggested progesterone could prevent threatened abortion might prevent habitual abortion oral bioavailability progesterone low injections progesterone painful orally active progestins tried beginning ethisterone followed progestins became available noretynodrel enovid norethisterone norlutin medroxyprogesterone acetate provera norethisterone acetate norlutate dydrogesterone duphaston first case reports fetal masculinization vulvas female infants born mothers treated pregnancy highdose ethisterone highdose norethisterone prevent miscarriage published march jama article pediatric endocrinologist lawson wilkins johns hopkins reported cases fetal masculinization vulvas female infants born mothers treated highdose mgday ethisterone prevent miscarriage cases fetal masculinization vulvas female infants born mothers treated highdose mgday norethisterone prevent ciba parkedavis added reported association ethisterone norethisterone masculinization vulva female fetus precautions section advertisements physicians physician prescribing clinical trial published october american journal obstetrics gynecology reported fetal masculinization vulvas female infants born mothers began highdose mgday norethisterone treatment prevent miscarriage first weeks pregnancy infants slight clitoral enlargement marked clitoral enlargement infants marked clitoral enlargement partial fusion labioscrotal folds fetal masculinization vulvas female infants born mothers began highdose mgday norethisterone treatment prevent miscarriage week pregnancy infant slight clitoral enlargement born mother began norethisterone treatment week parkedavis revised physician prescribing information norlutin norethisterone norlutate norethisterone acetate remove indications use infertility habitual abortion threatened abortion add pregnancy contraindication use possibility masculinization vulvas female fda determined adequate evidence progestogens including progesterone dydrogesterone caproate effective treating threatened abortion preventing habitual abortion withdrew approval published reports fetal masculinization vulva july fda published notice requiring black box warning progestogen drugs except contraceptives warn use first four months pregnancy reports nongenital birth citations january determining progestogens cause nongenital birth defects fda published notice revising black box warning progestogen drugs except contraceptives warn use first four months pregnancy past reports genital birth defects increased risk hypospadias male fetuses mild virilization vulvas female november fda published notice effective november removing years black box warning progestogen drugs unwarranted based scientific review current citations httpsenwikipediaorgwikiprogestininducedvirilization